NOVAREX Co (194700) Fair Value & Analysis
Consumer Defensive · KR · Market cap 257B KRW
Fair value as of: Jul 7, 2026
From 24 valuation models · updated today
Fair value updated Jul 7, 2026 — revised from 40,310 KRW to 37,660 KRW (−6.6%) since Jun 24, 2026. Share price −10.1% over the past month.
Price vs Fair Value (12 months)
12‑month range 11,600 KRW – 21,699 KRW · fair‑value band 26,935 KRW – 68,452 KRW · the 13,200 KRW price screens below the 37,660 KRW fair value. As of Jul 7, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
NOVAREX Co (194700) currently trades at 13,200 KRW, while our model-based Fair Value estimate is 37,660 KRW — implying the stock looks roughly 185.3% undervalued today. We read business quality at 56/100 (solid quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, NOVAREX Co generated revenue of 404B KRW at a net margin of 8.8%. Revenue grew 22.5% year over year. It earns a return on equity of 15.2%. Net debt stands at 18.3B KRW. Fundamentals as of Jul 7, 2026
Our scenario range runs from 26,935 KRW (bear case) to 68,452 KRW (bull case); at 13,200 KRW, the current price sits below that range. The share trades about 39% below its 52-week high and 15% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -17% fair-value upside — at 185%, 194700 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 7, 2026. TTM = trailing twelve months.
About the company
NOVAREX Co.,Ltd. manufactures, wholesales, and retails health and functional foods in South Korea and internationally. It offers lactic acid bacteria, omega-3, icle time, eye health, diet, boswellia, and lutein and zeaxanthin, as well as vitamin and mineral products in the form of tablets, soft and hard capsules, powder, liquid, gel, and jellies. The company was formerly known as Health Science Co., Ltd. and changed its name to NOVAREX Co.,Ltd. in November 2013. NOVAREX Co.,Ltd. was founded in 1995 and is headquartered in Cheongju-si, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
NOVAREX Co reported revenue of 404B KRW in FY2025 versus 279B KRW in FY2021, a compound +9.7%/yr. Reported net income was 35.4B KRW in FY2025, compounding +7.6%/yr from FY2021.
Is 194700 fairly valued? → Check now
Similar stocks
10 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Nestlé S.A NSRGF | $98.25 | $65.41 | -33% |
| Nestlé India Limited NESTLEIND | ₹1,438 | ₹362.37 | -75% |
| Grupo Bimbo, S.A. BIMBOA | 57.10 MXN | 83.34 MXN | +46% |
| Uni-President Enterprises Corp 1216 | 73.80 TWD | 61.57 TWD | -17% |
| Britannia Industries Limited BRITANNIA | ₹5,218 | ₹3,567 | -32% |
| Tata Consumer Products Limited TATACONSUM | ₹1,131 | ₹339.05 | -70% |
| ICBP ICBP | 6,600 IDR | 14,500 IDR | +120% |
| Samyang Foods Co 003230 | 1,000,000 KRW | 1,010,543 KRW | +1% |
| PT Indofood Sukses Makmur Tbk INDF | 6,250 IDR | 22,853 IDR | +266% |
| Patanjali Foods Limited PATANJALI | ₹420.45 | ₹294.68 | -30% |
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is NOVAREX Co (194700) undervalued?
What is the fair value of 194700?
What is the quality score of 194700?
What is the revenue of NOVAREX Co (194700)?
What is the net profit margin of 194700?
Does NOVAREX Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.